HHS moves to let pharmacies sell unapproved peptides

The Department of Health and Human Services posted a draft policy on Wednesday that allows specialty pharmacies to sell six specific wellness peptides without the usual federal safety review. The measure takes effect after a two-week public comment period. It directly contradicts the long-standing position of Food and Drug Administration scientists who opposed the change.

The policy targets a group of injectable compounds promoted for muscle building, injury healing, and energy boosts. These substances include BPC-157, TB-500, and KPV. Under current FDA rules, these chemicals are illegal drugs because they have not undergone the agency's rigorous testing for safety and effectiveness. The new directive instructs the FDA not to take action against pharmacies that sell them.

Health Secretary Robert F. Kennedy Jr. described the change as a way to advance patient choice and freedom. He stated that the policy protects Americans from peptides sold online that often contain unscreened ingredients. Kennedy has previously called himself a big fan of the treatments and noted that he used BPC-157 to treat a personal muscle injury.

FDA scientific staffers expressed strong opposition during the drafting process. They warned that the move could undermine the agency's mission to keep unproven products off the U.S. market. The group ultimately provided technical assistance to the HHS plan, adding guardrails such as requiring pharmacies to use ingredients from FDA-registered factories. They also included requirements for collecting side effect data and verifying peptide purity.

Dr. Peter Lurie, who leads the Center for Science in the Public Interest, questioned the timing of the decision. He noted that the FDA has already approved rigorously tested drugs for the conditions these peptides target, including insomnia, anxiety, and migraines. Lurie argued that diverting patients toward unproven substances could lead to unnecessary pain and suffering.

The peptide market has attracted major telehealth providers. Hims & Hers recently announced plans to offer wellness peptides once the government changed its policy. Wall Street analysts estimate the sector could be worth more than $2 billion. Lee Rosebush of the American Academy of Peptide Medicine called the HHS action a huge step for medical freedom, though the group represents sellers and prescribers rather than a traditional professional body.

Decisions regarding compounding pharmacies have historically fallen under FDA jurisdiction. Former FDA officials said it is rare for HHS to lead policy drafting in this area. The agency gained attention after a 2012 outbreak of fungal meningitis linked to contaminated injections from a Massachusetts pharmacy. The Alliance for Pharmacy Compounding said it needs clarity on when the policy takes effect and how it will interact with state pharmacy boards.